Published in J Pharm Sci on August 01, 1983
Bactrian ("double hump") acetaminophen pharmacokinetics: a case series and review of the literature. J Med Toxicol (2010) 0.88
Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. Br J Clin Pharmacol (2013) 0.87
Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. Br J Clin Pharmacol (2015) 0.78
Intravenous versus Oral Acetaminophen for Pain: Systematic Review of Current Evidence to Support Clinical Decision-Making. Can J Hosp Pharm (2015) 0.77
Quantitation of small intestinal permeability during normal human drug absorption. BMC Pharmacol Toxicol (2013) 0.77
Pharmacokinetic properties of intramuscular versus oral syrup paracetamol in Plasmodium falciparum malaria. Malar J (2016) 0.75
A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther (1981) 69.83
Drug therapy. Clinical Pharmacokinetics (first of two parts). N Engl J Med (1975) 7.60
Clinical pharmacokinetics (second of two parts). N Engl J Med (1975) 3.17
Use of benzodiazepines in anxiety disorders. N Engl J Med (1993) 3.12
Drug therapy: drug disposition in old age. N Engl J Med (1982) 3.04
Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet (2000) 2.94
Midazolam: pharmacology and uses. Anesthesiology (1985) 2.89
Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med (1981) 2.68
Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol (1980) 2.48
Intramuscular injection of drugs. N Engl J Med (1976) 2.20
Impairment of antipyrine clearance in humans by propranolol. Circulation (1978) 2.18
Diazepam disposition determinants. Clin Pharmacol Ther (1980) 2.16
Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology (1984) 2.14
Toxicity of high-dose flurazepam in the elderly. Clin Pharmacol Ther (1977) 2.05
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos (2000) 1.87
Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol (1996) 1.86
Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry (1990) 1.84
Automated gas chromatography for studies of midazolam pharmacokinetics. Anesthesiology (1981) 1.78
Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. Br J Clin Pharmacol (1978) 1.65
Clinical pharmacokinetics of quinidine. Clin Pharmacokinet (1980) 1.59
Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol (1981) 1.59
Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA (1973) 1.54
Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program. Drugs (1974) 1.54
Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations. Drug Metab Rev (1978) 1.54
Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther (2001) 1.52
Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos (2001) 1.47
Oxazepam kinetics: effects of age and sex. J Pharmacol Exp Ther (1980) 1.47
Clinical toxicity of furosemide in hospitalized patients. A report from the Boston Collaborative Drug Surveillance Program. Am Heart J (1977) 1.43
High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther (2012) 1.43
Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med (1980) 1.42
Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol (1997) 1.42
Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam. J Chromatogr (1978) 1.41
Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am J Psychiatry (2000) 1.40
Drug transporters in psychopharmacology--are they important? J Clin Psychopharmacol (2000) 1.40
In vitro quantitation of benzodiazepine lipophilicity: relation to in vivo distribution. Br J Anaesth (1983) 1.39
Drug therapy. Current status of benzodiazepines. N Engl J Med (1983) 1.39
MAOIs and hypertension. J Clin Psychopharmacol (1992) 1.39
Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol (1996) 1.39
Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci (1979) 1.37
Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. Cardiology (1984) 1.37
Effect of midazolam infusion and flumazenil administration on epinephrine arrhythmogenicity in dogs anesthetized with halothane. Anesthesiology (1993) 1.37
Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry (1990) 1.35
Lorazepam kinetics in the elderly. Clin Pharmacol Ther (1979) 1.35
Pharmacokinetic and clinical implications of quinidine protein binding. J Pharm Sci (1979) 1.34
Absorption and disposition of chlordiazepoxide in young and elderly male volunteers. J Clin Pharmacol (1978) 1.33
Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther (1999) 1.32
Nalidixic acid and hydroxynalidixic acid analysis in human plasma and urine by liquid chromatography. J Pharm Sci (1973) 1.32
Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet (1981) 1.31
Kinetics of intravenous and intramuscular morphine. Clin Pharmacol Ther (1978) 1.29
Clinical implications of benzodiazepine pharmacokinetics. Am J Psychiatry (1977) 1.29
Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther (1981) 1.29
Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology (2001) 1.29
Intramuscular injection-site complications. JAMA (1978) 1.28
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol (2001) 1.28
Ca(2+) sensors of L-type Ca(2+) channel. FEBS Lett (2000) 1.26
Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther (2007) 1.25
High-pressure liquid chromatographic analysis of antipyrine in small plasma samples. J Pharm Sci (1979) 1.25
Glycoconjugates as noninvasive probes of intrahepatic metabolism: pathways of glucose entry into compartmentalized hepatic UDP-glucose pools during glycogen accumulation. Proc Natl Acad Sci U S A (1986) 1.24
Population study of triazolam pharmacokinetics. Br J Clin Pharmacol (1986) 1.24
Acute overdosage with benzodiazepine derivatives. Clin Pharmacol Ther (1977) 1.24
Molecular determinants of L-type Ca2+ channel inactivation. Segment exchange analysis of the carboxyl-terminal cytoplasmic motif encoded by exons 40-42 of the human alpha1C subunit gene. J Biol Chem (1998) 1.24
Desmethyldiazepam kinetics in the elderly after oral prazepam. Clin Pharmacol Ther (1980) 1.21
The effect of pharmaceutical benefits managers: is it being evaluated? Ann Intern Med (1996) 1.21
Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity. J Pharmacol Exp Ther (1982) 1.19
High-performance liquid chromatographic determination of acetaminophen in plasma: single-dose pharmacokinetic studies. J Chromatogr (1981) 1.19
Pharmacokinetics and clinical effects of amantadine in drug-induced extrapyramidal symptoms. J Clin Pharmacol (1978) 1.19
Acetaminophen. Ann Intern Med (1977) 1.19
Reduced serum albumin concentration in the elderly: a report from the Boston Collaborative Drug Surveillance Program. J Am Geriatr Soc (1979) 1.19
Withdrawal reaction from long-term, low-dosage administration of diazepam. A double-blind, placebo-controlled case study. Arch Gen Psychiatry (1980) 1.18
In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos (2000) 1.18
Adverse reactions to intravenous diazepam: a report from the Boston Collaborative Drug Surveillance Program. Am J Med Sci (1973) 1.17
Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol (1985) 1.17
Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos (2000) 1.16
Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther (1996) 1.16
Effect of age and gender on disposition of temazepam. J Pharm Sci (1981) 1.16
Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol (1998) 1.16
Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos (2001) 1.15
Serum protein signatures detect early radiographic osteoarthritis. Osteoarthritis Cartilage (2008) 1.15
Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. Rev Infect Dis (1982) 1.14
Drug therapy. Current status of benzodiazepines. N Engl J Med (1983) 1.14
In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. J Pharmacol Exp Ther (1983) 1.14
Adverse reactions to propranolol in hospitalized medical patients: a report from the Boston Collaborative Drug Surveillance Program. Am Heart J (1973) 1.13
Variability of 24-hour urinary creatinine excretion by normal subjects. J Clin Pharmacol (1976) 1.13